402 related articles for article (PubMed ID: 26899534)
1. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
[TBL] [Abstract][Full Text] [Related]
2. Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway.
Kulshrestha A; Katara GK; Ibrahim SA; Riehl V; Sahoo M; Dolan J; Meinke KW; Pins MR; Beaman KD
J Oncol; 2019; 2019():2343876. PubMed ID: 31057611
[TBL] [Abstract][Full Text] [Related]
3. Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer.
Kulshrestha A; Katara GK; Ibrahim S; Pamarthy S; Jaiswal MK; Gilman Sachs A; Beaman KD
Oncotarget; 2015 Feb; 6(6):3797-810. PubMed ID: 25686833
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses.
Kulshrestha A; Katara GK; Ibrahim SA; Riehl VE; Schneiderman S; Bilal M; Young AN; Levine S; Fleetwood S; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2020 Oct; 14(10):2436-2454. PubMed ID: 32797726
[TBL] [Abstract][Full Text] [Related]
5. RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.
Mao D; Che J; Han S; Zhao H; Zhu Y; Zhu H
Mol Med Rep; 2015 Nov; 12(5):6635-41. PubMed ID: 26299671
[TBL] [Abstract][Full Text] [Related]
6. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment.
Hernlund E; Hjerpe E; Avall-Lundqvist E; Shoshan M
Mol Cancer Ther; 2009 Jul; 8(7):1916-23. PubMed ID: 19567816
[TBL] [Abstract][Full Text] [Related]
7. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
8. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
9. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
10. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
[TBL] [Abstract][Full Text] [Related]
11. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
12. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
13. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
16. PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer.
Salvi A; Young AN; Huntsman AC; Pergande MR; Korkmaz MA; Rathnayake RA; Mize BK; Kinghorn AD; Zhang X; Ratia K; Schirle M; Thomas JR; Brittain SM; Shelton C; Aldrich LN; Cologna SM; Fuchs JR; Burdette JE
Cell Death Dis; 2022 Jan; 13(1):45. PubMed ID: 35013112
[TBL] [Abstract][Full Text] [Related]
17. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
[TBL] [Abstract][Full Text] [Related]
18. ATP11B mediates platinum resistance in ovarian cancer.
Moreno-Smith M; Halder JB; Meltzer PS; Gonda TA; Mangala LS; Rupaimoole R; Lu C; Nagaraja AS; Gharpure KM; Kang Y; Rodriguez-Aguayo C; Vivas-Mejia PE; Zand B; Schmandt R; Wang H; Langley RR; Jennings NB; Ivan C; Coffin JE; Armaiz GN; Bottsford-Miller J; Kim SB; Halleck MS; Hendrix MJ; Bornman W; Bar-Eli M; Lee JS; Siddik ZH; Lopez-Berestein G; Sood AK
J Clin Invest; 2013 May; 123(5):2119-30. PubMed ID: 23585472
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
